NASDAQ:RANI

Rani Therapeutics Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy RANI

*Your capital is at risk

$0.774

-0.0462 (-5.63%)

At Close: Jul 31, 2026

Rani Therapeutics Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -43.34. In total, the insiders bought 19.36M and sold 6.56M RANI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-43.34
● Buy	19.36M shares
● Sell	6.56M shares
75% Buy Activity Moderate Positive Correlation
Buy Signal Low Confidence Jul 17, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -43.34. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 21, 2026 Buy	Class A Common Stock P-Purchase	Imran Mir A	Director	36 000 Value: $24.8K
Jul 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Maestas Nicholas Chief Financial Officer	C-Suite Officer	2 000 000 Value: $1.39M
Jul 17, 2026 Buy	Class A Common Stock P-Purchase	Imran Talat Chief Executive Officer	CEO / President	35 000 Value: $25.2K
Jun 29, 2026 Buy	Common Stock J-Other	Maestas Nicholas Insider	Other	0 Value: $0
Jun 27, 2026 Sell	Class A Common Stock F-InKind	Imran Talat Chief Executive Officer	CEO / President	7 927 Value: $6K
Jun 27, 2026 Sell	Class A Common Stock F-InKind	Javadi Alireza Chief Technical Officer	Officer	309 Value: $229
Jun 03, 2026 Buy	Stock Option (Right to Buy) A-Award	Imran Talat Chief Executive Officer	CEO / President	3 800 000 Value: $3.33M
Jun 03, 2026 Buy	Stock Option (Right to Buy) A-Award	Javadi Alireza Chief Technical Officer	Officer	805 500 Value: $704.8K
Jun 03, 2026 Buy	Stock Option (Right to Buy) A-Award	Mckinley Kate Chief Business Officer	Officer	805 500 Value: $704.8K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Ausiello Dennis A Director	Director	123 600 Value: $117.6K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Bassan Abraham Director	Director	123 600 Value: $117.6K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Rometty Lisa Ann Director	Director	123 600 Value: $117.6K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Imran Mir A	Director	123 600 Value: $117.6K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Butel Jean Luc Director	Director	123 600 Value: $117.6K
May 28, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Bailey Vasudev Jaiprakash Director	Director	123 600 Value: $117.6K
Mar 27, 2026 Sell	Class A Common Stock S-Sale	Javadi Alireza Chief Technical Officer	Officer	386 Value: $301
Mar 27, 2026 Sell	Class A Common Stock F-InKind	Imran Talat Chief Executive Officer	CEO / President	9 099 Value: $7K
Mar 22, 2026 Sell	Class A Common Stock F-InKind	Imran Talat Chief Executive Officer	CEO / President	8 916 Value: $10.1K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Javadi Alireza Chief Technical Officer	Officer	159 000 Value: $98.1K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Javadi Alireza Chief Technical Officer	Officer	40 750 Value: $146.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Javadi Alireza Chief Technical Officer	Officer	17 084 Value: $48.5K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Javadi Alireza Chief Technical Officer	Officer	3 416 Value: $18.6K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Javadi Alireza Chief Technical Officer	Officer	9 166 Value: $121.1K
Mar 18, 2026 Buy	Class A Common Stock	Javadi Alireza Chief Technical Officer	Officer	0 Value: $0
Dec 27, 2025 Sell	Class A Common Stock F-InKind	Imran Talat Chief Executive Officer	CEO / President	7 906 Value: $11.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RANI THERAPEUTICS HOLDINGS, INC.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...

Read Full Profile Here